New Oncotype DX® Data Presented at 2014 San Antonio Breast Cancer Symposium Further Demonstrate the Practice-Changing Impact of the Test in Guiding the Treatment of Early Stage Breast Cancer

Uncategorized December 16, 2014 at 9:27 AM 0 comments

 First prospective outcomes data reinforce the Oncotype DX test’s unique value in informing treatment decisions  Positive results of second large, independent validation study in DCIS breast cancer  GENEVA, Switzerland, [December 15, 2014] – Genomic Health announced presentation of the first prospective outcomes data from a large adjuvant study with theRead More

Gilead Presents Follow-Up Data from Idelalisib (Zydelig®) Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

Uncategorized December 11, 2014 at 11:33 AM 0 comments

– Results Describing Long-Term Safety and Disease Control Presented at the 56th American Society of Hematology Annual Meeting – San Francisco, December 10, 2014 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and the safety profileRead More

Gilead Presents Follow-Up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

Uncategorized December 9, 2014 at 4:41 PM 0 comments

– Results Describing Long-Term Safety and Disease Control Presented at the 56th American Society of Hematology Annual Meeting – SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig® (idelalisib) in relapsed patients with chronicRead More

UEG Puts the Need for Better Care for IBD Patients in Europe on the Political Agenda

Uncategorized December 2, 2014 at 4:14 PM 0 comments

(Vienna, 02, December, 2014) With inflammatory bowel disease (IBD) thought to cost the European Community over €2 billion in annual healthcare costs, United European Gastroenterology (UEG) is calling for EU politicians and leading decision-makers to take a more active role in reducing the burden of the disease. Presenting the resultsRead More

Experts Call for Greater Awareness of Alcohol Related Liver Disease and Liver Cancer

Uncategorized November 25, 2014 at 11:29 AM 0 comments

Awareness Week for Alcohol Related Harm 24th – 29th November 2014 Experts call for greater awareness of alcohol related liver disease and liver cancer Vienna, 24 November 2014 – United European Gastroenterology (UEG) is supporting the second annual Awareness Week on Alcohol Related Harm (AWARH) and calls for greater awarenessRead More

High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pre-Treated with VEGF-Targeted Therapies

Uncategorized November 24, 2014 at 11:37 AM 0 comments

Lugano/Geneva, Switzerland, 24 November 2014 – High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland. Lead author Dr Manon Evans, research fellow at the Christie Hospital in Manchester, UK, said:Read More

Immune Checkpoint Inhibitors May Work in Brain Cancers

Uncategorized November 21, 2014 at 12:17 PM 0 comments

LUGANO/GENEVA, Switzerland, 21 November 2014 – New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland. The novel research shows that brain metastases have dense concentrations of tumour infiltratingRead More

Possibilities for Personalised Vaccines Revealed at ESMO Symposium

Uncategorized November 21, 2014 at 12:11 PM 0 comments

LUGANO/GENEVA, Switzerland, 21 November 2014 – The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland. “One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancerRead More

The Oncotype DX® Test and Precision Oncology: New Data Presented at ESMO Further Demonstrate Genomic Health’s Successful Approach to Understanding Tumour Biology

Uncategorized October 6, 2014 at 9:39 AM 0 comments

Presentation of positive results from additional prostate cancer clinical validation study Further evidence of the practice-changing impact of the Oncotype DX test in breast cancer  GENEVA, Switzerland, [September 29, 2014] — In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress – ‘Precision MedicineRead More

ESMO Announces 15 New Designated Centres of Integrated Oncology and Palliative Care

Uncategorized September 29, 2014 at 10:14 AM 0 comments

Lugano, 19 September 2014 – Gaps in palliative care for cancer patients are revealed in new research to be presented later at the ESMO 2014 Congress in Madrid, Spain, 26-30 September. The findings come as 15 oncology centres in Europe, Canada, South America and Africa are awarded the prestigious titleRead More